Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQK5ET)

Drug Name
NG-350A Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMQK5ET

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40L receptor (CD40) TTN6Y9A TNR5_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
CD40L receptor (CD40) DTT CD40 4.629 4.991 5.53 3.385
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD40L receptor (CD40) DTT CD40 4.61E-01 0.56 0.5
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03852511) First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.